More Mesothelioma Cancer Centers Using Tumor Treating Fields
Tumor Treating Fields is one of the newest treatments on the market for pleural mesothelioma cancer patients with metastatic disease. The device is also available to patients with locally advanced cancer who are not candidates for mesothelioma surgery.
Clinical trials of the treatment, previously known as NovoTTF-100L, extended the survival of mesothelioma patients by more than six months compared to those receiving only chemotherapy.
The device is now called Optune Lua and has been available outside of clinical trials for over a year. More physicians and treatment centers are becoming certified to prescribe the treatment alongside pemetrexed (Alimta) and platinum-based chemotherapy.
Over 100 Physicians Now Prescribing Optune Lua
Novocure, the device’s manufacturer, recently announced that more than 100 physicians from over 50 cancer treatment centers within the U.S. are certified to prescribe Optune Lua.
At least 28 of the 50 certified centers are actively offering Optune Lua to malignant pleural mesothelioma patients. Additional centers are working toward completing all certification requirements.
Notable centers currently prescribing Optune Lua include:
Miami Cancer Institute
Cleveland Clinic Cancer Institute
Oregon Health & Science University
West Cancer Center & Research Institute
Beaumont Hospital
New mesothelioma treatments options provide hope to patients with this rare disease, explained Dr. Matthew T. Ballo, professor and...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Fran Mannino Source Type: news
More News: Alimta | Asbestosis | Baylor College of Medicine | Brain | Brain Cancers | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Environmental Health | Epithelial Cancer | Hospitals | Lung Cancer | Medical Devices | Mesothelioma | Neurology | Rare Diseases | Science | Skin | Toxicology